Landcadia Holdings IV, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LCA research report →
Price Chart
About the company
Landcadia Holdings IV, Inc. currently does not have substantial ongoing business operations. Its primary objective is to execute a strategic acquisition or a similar corporate combination with another entity, focusing its search within the consumer, dining, hospitality, entertainment, and gaming sectors.
- CEO
- Tilman J. Fertitta
- IPO
- 2021
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on LCA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $142.91M
- P/E
- 5.49
- PEG
- -0.43
- P/S
- 0.00
- P/B
- 53.79
- EV/EBITDA
- -112.96
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 10.18%
- ROIC
- -8.93%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,265,245
- Net Income
- $23.97M+160.7%
- EPS
- $1.92+418.9%
- OCF Growth
- +73.9%
- FCF Growth
- +73.9%
- 52W High
- $10.56
- 52W Low
- $10.04
- 50D MA
- $10.50
- 200D MA
- $10.36
- Beta
- 0.00
- RSI (14)
- 62
- Avg Volume
- 4.85K
No earnings-call transcripts are available for LCA yet.
- Free Float
- 7.8%
- Shares Outstanding
- 13.56M
- Float Shares
- 1.06M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Omni Partners Us LLC | 512.01K | ▲ 1.23K |
Held by 1 ETFs
Biggest fund positions in LCA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 24 | TJF, LLC | other | 6,250,000 |
| Mar 20, 24 | Jefferies Financial Group Inc. | other | 6,250,000 |
| Oct 2, 23 | Jefferies Financial Group Inc. | other | 6,250,000 |
| Oct 2, 23 | Jefferies Financial Group Inc. | other | 6,250,000 |
| Oct 2, 23 | TJF, LLC | other | 6,250,000 |
| Oct 2, 23 | TJF, LLC | other | 6,250,000 |
| Mar 25, 22 | CHADWICK MICHAEL S | other | 0 |
| May 10, 21 | TJF, LLC | sell | 937,500 |
| May 10, 21 | Jefferies Financial Group Inc. | sell | 937,500 |
| Mar 24, 21 | TJF, LLC | other | 7,187,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LCA coverage
Recent articles, reports, and earnings notes.
No research on LCA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LCA report →Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
globenewswire.com · Aug 3
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
globenewswire.com · Jul 6
Vontier Surpasses 2030 Emissions Target Five Years Early, Sets New 65% Reduction Goal
gurufocus.com · Jun 11
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
globenewswire.com · May 4
Opus Genetics: Asymmetric Upside With LCA5 And BEST1
seekingalpha.com · Feb 22
Beyond Meat® Releases 2024 Corporate Responsibility Report and LCA Study that Estimates Environmental Benefits of Beyond Burger® IV, Submits to CDP for First Time
globenewswire.com · Dec 23
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
globenewswire.com · Nov 6
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.